What is clear is the necessity for just a unified and focused approach to disarming the fake pharma marketplace, with Every company and state addressing their unique vulnerabilities. But just what does this appear to be?In July 2011, the EU strengthened the protection of individuals and customers by adopting a different Directive on falsified medic